云顶新耀就布地奈德肠溶胶囊仿制药获批发布声明：公司原研产品尚在专利保护期内
EVEREST MEDEVEREST MED(HK:01952) Cai Jing Wang·2025-12-25 08:36

Core Viewpoint - The company has noted the approval of a generic version of its marketed product Budesonide Enteric-Coated Capsules (Nafacon) [1] Group 1 - The original product Nafacon is protected by patent ZL200980127272.5 in China, which is currently valid until May 7, 2029 [1] - The company reserves the right to take legal action against any infringement of the patent rights and commitments [1]